What is Range Biotechnologies?
Founded in 2022, Range Biotechnologies operates at the intersection of advanced proteomics and computational biology. The company is dedicated to mapping the proteome with unprecedented precision, a critical endeavor for modern drug discovery and personalized medicine. By focusing on the complex interactions of proteins, the firm provides essential data-driven insights that traditional genomic approaches often overlook.
The company's market position is defined by its commitment to engineering-first methodologies, which allow for the rapid iteration of diagnostic and therapeutic solutions. As a key player in the emerging Tech Bio space, Range Biotechnologies is effectively bridging the gap between raw biological data and actionable clinical outcomes, positioning itself as an essential partner for pharmaceutical entities and research institutions alike.
How much funding has Range Biotechnologies raised?
Range Biotechnologies has raised a total of $5.2M across 1 funding round:
Angel/Seed
$5.2M
Angel/Seed (2023): $5.2M with participation from Civilization Ventures, Page One Ventures, Artis Ventures Management Iii, and Pear VC
Key Investors in Range Biotechnologies
Civilization Ventures
A venture capital firm specializing in health tech and biopharma, focusing on preventative and regenerative healthcare solutions with a strong track record in genomics and diagnostics.
Artis Ventures Management Iii
A dedicated fund focused on Tech Bio and life sciences, leveraging an engineering-first approach to support data-driven companies aiming to enhance human health.
Pear VC
A seed-stage investment firm that partners with founders to provide talent recruitment, fundraising support, and go-to-market strategies for early-stage startups.
What's next for Range Biotechnologies?
Looking ahead, the strategic deployment of the $5.2M will likely focus on scaling the company's core proteomics engine and expanding its footprint in the biopharma ecosystem. The management team is expected to prioritize the acquisition of top-tier talent in bioinformatics and protein engineering to maintain its competitive edge. Furthermore, the firm is poised to initiate key partnerships that will facilitate the integration of its technology into existing drug discovery pipelines.
As the company matures, the focus will shift toward commercializing its platform and demonstrating clinical utility. With the backing of high-profile venture capital firms, Range Biotechnologies is well-equipped to navigate the complexities of the biotechnology market, aiming to deliver long-term value through the development of curative therapies and innovative health solutions.
